Oblique Therapeutics

About:

Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic cancer.

Top Investors: Almi Invest

Description:

Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic cancer. Oblique Therapeutics is an early stage innovation-driven pharmaceutical company aiming at developing transformative medicines against advanced and metastatic cancer.

Total Funding Amount:

$2.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Göteborg, Vastra Gotaland, Sweden

Founded Date:

2015-01-01

Contact Email:

info(AT)obliquet.com

Founders:

Carolina Trkulja, Owe Orwar

Number of Employees:

1-10

Last Funding Date:

2015-12-11

IPO Status:

Private

Industries: